Latest Breaking News On - Orphan drug designations - Page 1 : vimarsana.com

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response and two stable disease observations have occurred as of May 15,.

United kingdomUnited statesPrehevbrio prehevbriBrii biosciencesDavide andersonJeff baxterCompany quarterly reports on formAmerican society of clinical oncologyVaccines incOncology centerDrug administrationClinical oncologyAnnual meetingScientific officerFast trackOrphan drug designations

NLS Pharmaceutics AG: NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol s Neuroprotective Effects in Narcoleptic-like Rat Model

ZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies

United statesEric konofalEuropean medicines agencyCompany contactsExchange commissionPharmaceutics ltdAmerican society of clinical psychopharmacologyAmerican societyClinical psychopharmacologyChief scientific officerNocturnal activityOrexinb saporin induced narcoleptic like modelDependent responseActivity monitoringOrphan disease designationMazindol controlled release

NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol s Neuroprotective Effects in Narcoleptic-like Rat Model

NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol s Neuroprotective Effects in Narcoleptic-like Rat Model
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

United statesEric konofalAmerican society of clinical psychopharmacologyPharmaceutics ltdEuropean medicines agencyExchange commissionCompany contactsAmerican societyClinical psychopharmacologyChief scientific officerNeuroprotective effectNocturnal activityOrexinb saporin induced narcoleptic like modelDependent responseActivity monitoringOrphan disease designation

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

Pharmaceutics ltdStaff of the listing qualifications departmentNasdaq hearings panelNasdaq hearings panel theNasdaq stock marketEuropean medicines agencyListing qualifications departmentListing ruleNasdaq listing ruleNasdaq capitalOrphan disease designationMazindol controlled releaseOrphan drug designationsRisk factor

NLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq

NLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Pharmaceutics ltdNasdaq hearings panel theStaff of the listing qualifications departmentNasdaq stock marketNasdaq hearings panelEuropean medicines agencyListing qualifications departmentListing ruleNasdaq listing ruleNasdaq capitalOrphan disease designationMazindol controlled releaseOrphan drug designationsIhr portfolio